Retrospective survey of fluoroquinolone use in children;Enquete retrospective sur l'utilisation des fluoroquinolones en pediatrie

Archives de Pediatrie

Volumn 5, Issue 5, 1998, Pages 484-488

  Pariente Khayat, A ^a   Vauzelle Kervroedan, F ^a   D'Athis, P ^a   Breart G ^b   Gendrel, D ^a   Aujard, Y ^c   Olive, G ^a   Pons, G ^a  

^a HÔPITAL SAINT VINCENT DE PAUL   (France)

^b Hôpital Cochin ^*  (France)

^c HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

Child; Epidemiology; Pharmacology, clinical; Quinolones; Retrospective studies

Indexed keywords

CIPROFLOXACIN; NORFLOXACIN; OFLOXACIN; PEFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ADOLESCENT; ADULT; ARTHRALGIA; ARTHRITIS; ARTICLE; CHILD; CYSTIC FIBROSIS; DIARRHEA; DRUG ERUPTION; FEMALE; HUMAN; INFANT; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PHOTOSENSITIVITY; PRESCRIPTION; RETROSPECTIVE STUDY; VOMITING; DRUG UTILIZATION; FRANCE; PRESCHOOL CHILD;

ADOLESCENT; ANTI-INFECTIVE AGENTS; CHILD; CHILD, PRESCHOOL; DRUG UTILIZATION; FEMALE; FLUOROQUINOLONES; FRANCE; HUMANS; INFANT; MALE; RETROSPECTIVE STUDIES;

EID: 0032060298     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-693X(99)80311-X     Document Type: Article

References (29)

1. 1 Christ W, Lehnert T, Ulbrich B. Specific toxicologic aspects of the quinolones. Rev Infect Dis 1988 ; 10 Suppl 1 : 141-6
2. 2 Javier RM, Sibilia J, Kuntz JL, Asch L. Effets indésirables rhumatologiques des quinolones. Sem Hôp Paris 1992 ; 68 : 795-800
3. 3 Grenier B. Évaluation de la toxicité des quinolones en pédiatrie. In : Aujard Y, Gendrel D, eds. Les quinolones en pédiatrie. Paris : Flammarion Médecine-Sciences ; 1994. p 117-22
4. 4 Schaad UB. Use of the quinolones in paediatrics. Drugs 1993 ; 45 Suppl 3 : 37-41
5. 5 Gendrel D, Aujard Y. Les quinolones en pédiatrie. Arch Pédiatr 1995 ; 2 : 409-11
6. 6 Dagan R. Fluoroquinolones in paediatrics - 1995. Drugs 1995 ; 49 Suppl 2 : 92-9
7. 7 Lietman PS. Fluoroquinolones toxicities. Drugs 1995 ; 49 Suppl 2 : 159-63
8. 8 Vauzelle-Kervroëdan F, Pariente-Khayat A, Pons G, Olive G. Pharmacovigilance et quinolones en pédiatrie. In : Aujard Y, Gendrel D, eds. Les quinolones en pédiatrie. Paris : Flammarion Médecine-Sciences ; 1994. p 111-5
9. 9 Kesseler A, Lacassie A, Hugot JP, Talon P, Thomas D, Astier L. Arthropathies consécutives à l'administration de péfloxacine chez un adolescent atteint de mucoviscidose, Ann Pédiatr 1989 ; 36 : 275-8
10. 10 Touzet P, Thibaud D. Hydarthrose compliquant un traitement de péfloxacine chez un adolescent de 14 ans. Arch Fr Pédiatr 1991 ; 48 : 151-4
11. 11 Seigneuric C, Plantavid M, Bouygues D, Cassou M, Amar J, Cascarigny F. Manifestations articulaires sous péfloxacine chez l'adolescent [lettre]. Presse Méd 1990 ; 19 : 428
12. 12 Le Loët X, Fessard C, Noblet C, Ait Saït L, Moore N. Severe polyarthropathy in an adolescent treated with pefloxacin [letter]. J Rheumatol 1991 ; 18 : 1941-2
13. 13 Ollier S, Laroche M, Arlet P, Montane P, Durroux R, Le Tallec Y. Arthropathie à la péfloxacine. Rev Rhum Mal Ostéoartic 1990 ; 57 : 671
14. 14 Jawad ASM. Cystic fibrosis and drug-induced arthropathy [letter]. Br J Rheumatol 1989 ; 28 : 179-80
15. 15 Alfaham M, Holt ME, Goodchild MC. Arthropathy in a patient with cystic fibrosis taking ciprofloxacin [letter]. Br Med J Clin Res 1987 ; 295 : 699
16. 16 Pertuiset E, Lenoir G, Jehanne M, Douchain F, Guillot M, Menkes CJ. Tolérance articulaire de la péfloxacine et de l'ofloxacine chez les enfants et adolescents atteints de mucoviscidose. Rev Rhum Mal Ostéoartic 1989 ; 56 : 735-40
17. 17 Kuhn RJ, Palmejar A, Kanga JF. Tolerability of ciprofloxacin in pediatric patients with cystic fibrosis. Adv Antimicrob Antineopl Chemother 1992 ; 11-2 : 269-71
18. 18 Black A, Redmond AOB, Steen HJ, Oborska IT. Tolerance and safety of ciprofloxacin in paediatric patients. J Antimicrob Chemother 1990 ; 26 Suppl F : 25-9
19. 19 Schroëder DJ, Hart LL, Lynch SS. Potential quinolone. Induced cartilage toxicity in children. Ann Pharm 1994 ; 28 : 336-8
20. 20 Newman AJ, Ansell BM. Episodic arthritis in children with cystic fibrosis. J Pediatr 1979 ; 94 : 594-6
21. 21 Phillips BM, David TJ. Pathogenesis and management of arthropathy in cystic fibrosis. J Royal Soc Med 1989 ; 79 Suppl 12 : 144-50
22. 22 Schaad UB, Stoupis C, Wedgwood J, Tschaeppler H, Vock P. Clinical, radiologic and magnetic resonance monitoring for skeletal toxicity in pediatric patients with cystic fibrosis receiving a three-month course of ciprofloxacin. Pediatr Infect Dis J 1991 ; 10 : 723-9
23. 23 Danisovicová A, Krcméryová T, Belan S, Kayserova H, Hruskovic I, Brezina M et al. Magnetic resonance imaging in diagnosis of potential arthropathogenicity in children receiving quinolones. No evidence of quinolones-induced arthropathy. Drugs 1995 ; 49 Suppl 2 : 492-4
24. 24 Chevalier X, Albengres E, Voisin MC, Tillement JP, Larget-Piet B, A case of destructive polyarthropathy in a 17-year-old youth following pefloxacin treatment. Drug Saf 1992 ; 7 : 310-4
25. 25 Winrow AP, Supramaniam G. Benign intracranial hypertension after ciprofloxacin administration. Arch Dis Child 1990 ; 65 : 1165-6
26. 26 Davis H, McGoodwin E, Reed TG. Anaphylactoid reactions reported after treatment with ciprofloxacin. Ann Intern Med 1989 ; 111 : 1041-3
27. 27 Miller MS, Gaido F, Rourk MH, Spock A. Anaphylactoid reactions to ciprofloxacin in cystic fibrosis patients. Pediatr Infect Dis J 1991 ; 10 : 164-5
28. 28 Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K. Typhoid fever, ciprofloxacin and renal failure. Arch Dis Child 1991 ; 66 : 1083-4
29. 29 Lumbiganon P, Pengsaa K, Sookpranee T. Ciprofloxacin in neonates and its possible adverse effect on the teeth. Pediatr Infect Dis J 1991 ; 10 : 619-20